COVID-19 seroprevalence amongst healthcare workers: potential biases in estimating infection prevalence

Maddalena Cordioli1, Massimo Mirandola1, Lorenzo Gios1,2, Sebastiano Gaspari1, Maria Carelli4, Virginia Lotti4, Angela Sandri4, Caterina Vicentini5, Davide Gibellini4, Elena Carrara1, Evelina Tacconelli1 and the ENACT Working Group

1Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, Verona, Italy; 2School of Health Sciences, University of Brighton, Brighton, UK; 3Fondazione Bruno Kessler, Trento, Italy; 4Microbiology and Virology Section, Department of Diagnostics and Public Health, University of Verona, Verona, Italy and 5Microbiology Unit, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy

Abstract

SARS-CoV-2 serological tests are used to assess the infection seroprevalence within a population. This study aimed at assessing potential biases in estimating infection prevalence amongst healthcare workers (HCWs) when different diagnostic criteria are considered. A multi-site cross-sectional study was carried out in April–September 2020 amongst 1,367 Italian HCWs. SARS-CoV-2 prevalence was assessed using three diagnostic criteria: RT-PCR on nasopharyngeal swab, point-of-care fingerprick serological test (POCT) result and COVID-19 clinical pathognomonic presentation. A logistic regression model was used to estimate the probability of POCT-positive result in relation to the time since infection (RT-PCR positivity). Among 1,367 HCWs, 69.2% were working in COVID-19 units. Statistically significant differences in age, role and gender were observed between COVID-19/non-COVID-19 units. Prevalence of SARS-CoV-2 infection varied according to the criterion considered: 6.7% for POCT, 8.1% for RT-PCR, 10.0% for either POCT or RT-PCR, 9.6% for infection pathognomonic clinical presentation and 17.6% when at least one of the previous criteria was present. The probability of POCT-positive result decreased by 1.1% every 10 days from the infection. This study highlights potential biases in estimating SARS-CoV-2 point-prevalence data according to the criteria used. Although informative on infection susceptibility and herd immunity level, POCT serological tests are not the best predictors of previous COVID-19 infections for public health monitoring programmes.

Introduction

Since 21st February 2020 Italy reported cases of the 2019 coronavirus disease (COVID-19). As a consequence of the extraordinary containment measures implemented by the Italian Government between 8th March and 18th May 2020, the incidence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection progressively reduced and the first wave of the pandemic ended in early summer 2020 [1]. In total, 225 435 COVID-19 cases occurred in this period of time, 13.8% of them were lethal [2]. The Veneto Region resulted as one of the most affected area accounting, by October 2020, for the 8.7% of overall Italian cases (46,992) [3]. Within this scenario, healthcare workers (HCWs) were particularly exposed to SARS-CoV-2 infection considering their role of frontline workforces in the response to COVID-19 pandemic [4, 5].

Since April 2020, many serological tests have been developed to assess the infection seroprevalence and to estimate the progress towards the goal of reaching the herd immunity. As expected, for a novel disease like COVID-19, the diagnostic tests have limitations that might reduce their clinical and epidemiological validity. The first limit is related to the not perfect intrinsic analytical characteristics of the tests, particularly concerning the sensitivity and specificity, as pointed out by many authors [6–9]. The second, that is particularly evident when considering the point-of-care tests (POCT), is the gap between the performances achieved in the lab (usually based on plasma or serum) and those reported in real-life studies on fingerprick blood [10–13]. In addition, serological tests to detect SARS-CoV-2 are affected not only by the kinetic of antibody production, which requires few weeks to produce antibodies in such concentration to be detected in human blood [14], but also by the fact that SARS-CoV-2 antibodies decay over time [13].

Many papers have been published reporting SARS-CoV-2 seroprevalence amongst HCWs during COVID-19 first wave. However, their results are far from being solid and definitive as
based on point-prevalence studies which consider different types of tests with limited samples and different criteria for HCWs enrolment (i.e. surveillance, contact tracing/presence of symptoms, etc.). Positivity rates amongst HCWs ranged between 8.5% as described by Galanis et al. in their systematic review [15] to 11.8% as recently found in a large cross-sectional study in Spain [16]. However, SARS-CoV-2 prevalence varied largely according to clinical presentation as well described by Pallet et al. in the UK: 10.6% and 44.7% for asymptomatic and symptomatic HCWs, respectively, with an overall positivity rate of 18.0% [17]. The World Health Organization (WHO) estimated that HCWs accounted for approximately 14% of COVID-19 cases [18]. Similar rates have been reported in Italy where the proportion of HCWs amongst COVID-19 patients was found to be 9% [19]. This prevalence could be lower when considering HCWs as a target of specific monitoring programmes as part of overall risk surveillance. This is the case of a serosurvey carried out in the Veneto Region where SARS-CoV-2 infection seroprevalence among HCWs was found to be 4.6% [20]. As pointed out by a recent Cochrane systematic review on SARS-CoV-2 antibody tests [13], variation in SARS-CoV-2 seroprevalence is usually due to non-homogeneous data as they often consider either hospitalised or symptomatic cases or asymptomatic individuals.

This paper describes the findings of a study implemented with the aim of triangulating different sources of information (RT-PCR testing, POCT serological test results and self-reported symptoms) and assessing the potential bias in estimating SARS-CoV-2 prevalence when basing this calculation on different case definitions.

**Materials and methods**

**Population, setting, tools and procedure**

This is a cross-sectional multi-centre study carried out in the four main public hospitals in the Verona Province (Veneto Region, Italy), from 21st April to 14th September 2020. All hospitals were either indicated as COVID-19 province hub (devoted to confirmed SARS-CoV-2 cases) or general hospitals (providing essential non-COVID-19 services) with dedicated COVID-19wards.

HCWs from COVID-19 and non-COVID-19 units were recruited prospectively and asked to participate in the study signing the informed consent and completing an *ad hoc* online survey. An HCW was defined as a person who provide healthcare services both directly (i.e. doctors, nurses, midwives, etc.) or indirectly (i.e. laboratory technicians, admin staff, etc.) within the selected hospitals.

The survey was designed to collect socio-demographic characteristics, professional role, contacts with COVID-19 patients and colleagues, SARS-CoV-2 testing history and a list of signs and symptoms (S&S) HCWs might have experienced since February 2020. At the enrolment, HCWs were asked to fill in the electronic survey and being tested using the COVID-19 IgG/IgM rapid test (Healgen Scientific LLC, USA), henceforth named POCT, on fingerpicked blood. POCTs were performed and read by trained staff following manufacturer’s instructions and their results were recorded on a specific form. As described in POCT package insert, sensitivity is 96.7% (95% confidence interval (95% CI) 90.7–98.9), 86.7 (95% CI 78.1–92.2) and 96.7% (95% CI 90.7–98.9) for IgG, IgM and IgG/IgM component, respectively. As for specificity, the percentages are, respectively, 100% (95% CI 93.1–99.5), 99.0% (95% CI 94.6–99.8) and 97.0% (95% CI 91.6–99.0) [21].

For all HCWs with a positive POCT test and, based on the survey form, no previous history of COVID-19, RT-PCR on nasopharyngeal swab (NPS) was performed to ascertain the risk of SARS-CoV-2 transmission.

The study was approved by the local ethic committee (2653/2020CE\(2\)).

**Case definitions**

A COVID-19 case was defined as a person (i) with a history of positive SARS-CoV-2 RT-PCR on NPS and/or (ii) with a positive result of the POCT during the study and/or (iii) reporting, from February till April 2020, COVID-19 typical S&S [19–22]. The decision of including COVID-19 pathognomonic clinical presentation in the case definition was taken considering that SARS-CoV-2 antibody titres often decrease over time and that a massive molecular screening testing with RT-PCR was implemented since April 2020. Therefore, HCWs who acquired SARS-CoV-2 infection in the first 8 weeks of the pandemic might have resulted negative in both molecular and rapid serological tests. A COVID-19 case was considered (a) certain with COVID-19 pathognomonic S&S such as ‘agueusia/anosmia’ or ‘fever and/or cough and dyspnoea’ or ‘fever and nausea/vomit or diarrhoea’ since February 2020 or (b) possible when the following clinical conditions were reported: ‘fever and arthromyalgia’ or ‘fever and fatigue’ or aspecific symptoms without systemic involvement (headache, dizziness, pharyngalgia, confusion). Only HCWs who reported COVID-19 pathognomonic S&S were considered as SARS-CoV-2 cases.

As for SARS-CoV-2 diagnostic case, only HCWs who did result positive to either RT-PCR on NPS or the study POCT were included.

Therefore, for the estimation of the overall SARS-CoV-2 prevalence, we considered as numerator the number of HCWs who resulted positive to any SARS-CoV-2 diagnostic tests and/or reporting SARS-CoV-2 pathognomonic S&S in the first 8 weeks of the pandemic, while as denominator all study participants.

**Statistical analysis**

Mean, median, standard deviation and Wilcoxon comparison. For nominal variables, percentages were estimated, while Fisher’s exact test was used to estimate the association between categorical variables. The prevalence was estimated as percentage of proportion and 95% CI was based on logit transformation. A multivariate logistic model was used to estimate the probability of serological positive test result in relation to the date in which the test was performed. STATA Version 16.2 was used for analyses (College Station, TX, USA: StataCorp LP).

**Results**

**Study participants**

Overall, 1367 HCWs were enrolled in the study with a median age of 41.3 years. Socio-demographic characteristics of the study population are summarised in Table 1.

In total, 946 (69.2%) HCWs were working in COVID-19 units. In total, 399 (29.3%) were medical doctors, 724 (53.1%) were nurses, midwives or physiotherapists, 224 (16.4%) were healthcare assistants. Sixteen (1.2%) were diagnostic radiographers, biologists, administrative personnel, data managers or technicians.
In COVID-19 wards personnel was more frequently younger, male, healthcare assistant compared to non-COVID-19 units. A detailed list of statistically significant differences is presented in Table 1.

**SARS-CoV-2 infection prevalence**

In line with the case definitions, different prevalence estimates were calculated: 8.1% (95% CI 6.8–9.7) with RT-PCR on NPS, 6.7% (95% CI 5.5–8.1) with POCT, 9.6% (95% CI 8.1–11.3) with pathognomonic S&S. When both diagnostic tests were combined, the prevalence was 17.6% (95% CI 15.6–20.0). Table 2 presents the distribution of different COVID-19 estimates by COVID-19/non-COVID-19 units based on the different case definitions considered.

Ninety-one HCWs resulted positive to the POCT. Among them, 60 (65.9%) were positive only for IgG, five (5.5%) only for IgM, while 26 (28.6%) for both IgG and IgM. As far as the comparison between COVID-19 and non-COVID-19 wards is concerned, the number of HCWs positive for IgG was 26 (6.8%) and 60 (6.1%) respectively (P = 0.022), while for both IgG and IgM the positives were 72 (7.6%) and 19 (4.5%) (P = 0.034) (Table 2).

In total, 111 (8.1%) HCWs reported a previous COVID-19 diagnosis by RT-PCR on NPS. Among them, 85 (69.2%) were working in COVID-19 wards. Based on RT-PCR on NPS and POCT results, the diagnostic prevalence was 10.9% amongst HCWs working in COVID-19 units and 7.8% in those working in non-COVID-19 units. The difference was not statistically significant to 5% (P = 0.096).

Amongst them, 97 (75.8%) were working in COVID-19 units and 31 (24.2%) in non-COVID-19 units (P = 0.208).

Considering the presence of at least one of the case definitions considered, the overall SARS-CoV-2 prevalence was found 17.6%. COVID-19 personnel were more frequently positive (19.0%, 95% CI 15.6–20.0) than the non-COVID-19 HCWs (14.3%, 95% CI 11.2–17.9) (P = 0.037).

**Seropositivity over time**

Amongst the 111 HCWs with a reported previous SARS-CoV-2 diagnosis based on NPS RT-PCR, the number of individuals with a positive (IgG and/or IgM) POCT result was 66 (59.5%). As the date of the POCT and the first positive RT-PCR on NPS was recorded, it was possible to estimate the time interval. The median time was 125 days (102.2 ± 49.7). The median time difference between those who resulted positive (63.5 days ± 49.8, min 16–max 182) and negative (136 days ± 45.9, min 0–max 161) at the POCT was statistically significant (P = 0.0196).

Considering the HCWs working in COVID-19 units, we did not find any significant difference between those with a positive and a negative serology. In addition, amongst HCWs reporting both a previous RT-PCR positivity and COVID-19 pathognomonic S&S, the median time between these variables was found to be 1 day (iqr 5).

Based on a logistic model, the probability of seropositivity in relation to the time elapsed between the infection and the POCT was estimated. The model showed a decrease of 1.1% every 10 days since the date of RT-PCR first positive result for the IgG and/or IgM (OR 0.99, 95% CI 0.98–0.99, P = 0.009). This estimate varies according to the type of antibody considered. In particular for the IgM only, this probability seemed to decrease more rapidly (1.8%, OR 0.98, 95% CI 0.97–0.99, P = 0.001).

---

**Table 1. Socio-demographic characteristics of the HCWs enrolled in the study, by COVID-19 units**

|                      | Overall |                 |               |                 |                  |                  |      |
|----------------------|---------|-----------------|---------------|-----------------|------------------|------------------|------|
|                      | N       | %               | N             | %               | n                | n/N %            | P    |
| HCWs enrolled        | 1.367   | 1.367           | 100.0         | 946             | 69.2             | 421              | 30.8 |
| Gender               |         |                 |               |                 |                  |                  |      |
| Female               | 1.367   | 1.068           | 78.1          | 721             | 76.2             | 347              | 82.4 |
|                      |         | 299             | 21.9          | 225             | 23.8             | 74               | 17.6 |
| Male                 |         |                 |               |                 |                  |                  |      |
| Age                  |         |                 |               |                 |                  |                  |      |
| ≤25                  | 1.326   | 50              | 3.77          | 46              | 5.0              | 4                | 1.0  |
| ≥26 and <51          | 1.326   | 943             | 71.2          | 644             | 70.1             | 299              | 73.5 |
| >51                  | 1.326   | 333             | 25.1          | 229             | 24.9             | 104              | 25.5 |
|                      |         | 41.7            | 41.9          | 41.9             | 41.5             |                  |      |
|                      |         | 41.3            | 42.4          | 39.9             |                  |                  |      |
|                      |         | 11.0            | 11.0          | 11.1             |                  |                  |      |
|                      |         | 18.9            | 22.6          | 18.9             |                  |                  |      |
|                      |         | 69.6            | 67.1          | 69.6             |                  |                  |      |
| Role                 |         |                 |               |                 |                  |                  |      |
| Medical doctor       | 1.363   | 399             | 29.3          | 251             | 26.6             | 148              | 35.3 |
| Nurse/midwife/physiotherapist | 1.363 | 724             | 53.1          | 513             | 54.4             | 211              | 50.4 |
| Healthcare assistant | 1.363   | 224             | 16.4          | 175             | 18.5             | 49               | 11.7 |
| Other*               | 1.363   | 16              | 1.2           | 5               | 0.5              | 11               | 2.6  |

P values refer to the comparison of diagnostic results between COVID-19/non-COVID-19 units.

*Statistically significant (P < 0.05)
Overall COVID-19 units Non-COVID-19 units

| Percentage | Diagnostic prevalence (POCT + RT-PCR) | POCT-positive result | POCT-positive results |
|------------|---------------------------------------|----------------------|----------------------|
|            |                                       | IgG                  | IgM                  |
|            |                                       | IgG and/or IgM       |                      |
| N          |                                       | 72.7                 | 7.6                  |
| % 95% CI   |                                       | 5.1–8.1              | 6.1–9.5              |
| n/n       |                                       | 32.6                 | 26.8                 |
| P          |                                       | 0.62                 | 0.62                 |
| n/n %      |                                       | 26.8                 | 26.8                 |
|            |                                       | 26.8                 | 26.8                 |

**Table 2.** SARS-CoV-2 prevalence estimated amongst HCWs according to the criterion considered pathognomonic S&S, COVID-19 previous molecular diagnostic, POCT results, by place of work (in bold the condition for satisfying the criteria and being considered for analysis).

POCT-positive results

| Percentage | Diagnostic prevalence (POCT + RT-PCR) | POCT-positive result | POCT-positive results |
|------------|---------------------------------------|----------------------|----------------------|
|            |                                       | IgG                  | IgM                  |
|            |                                       | IgG and/or IgM       |                      |
| N          |                                       | 41.9                 | 9.1                  |
| % 95% CI   |                                       | 9.0–13.2             | 8.1–13.1             |
| n/n       |                                       | 32.6                 | 26.8                 |
| P          |                                       | 0.010                | 0.010                |
| n/n %      |                                       | 26.8                 | 26.8                 |
|            |                                       | 26.8                 | 26.8                 |

**Table 2.** SARS-CoV-2 prevalence estimated amongst HCWs according to the criterion considered pathognomonic S&S, COVID-19 previous molecular diagnostic, POCT results, by place of work (in bold the condition for satisfying the criteria and being considered for analysis).

POCT-positive results

**Figure 2** shows the number of HCWs who could be classified as having had a SARS-CoV-2 infection, based on the combination of the three case definitions used in this paper. In total, 240 HCWs resulted positive to at least one criterion, 76 to at least two criteria and 13 to all the three ones. Despite the limitation of pathognomonic S&S case definition, 104 HCWs with a probable SARS-CoV-2 infection would be missed if not considered.

**Discussion**

Italy was the first European Country to report autochthonous COVID-19 cases and the Veneto Region was one of the first areas in which these cases were diagnosed. The rapid onset of the pandemic’s spreading heavily exposed HCWs to SARS-CoV-2 infection. By 28th October 2020, 39,578 HCWs were diagnosed with COVID-19 (7.3% of the total cases) [26].

Since the development of the first serological test for SARS-CoV-2 infection, testing tools have been widely used [8] and a wide range of estimates on COVID-19 prevalence among HCWs ranging from 0% to 44.7% were published across countries [16, 17, 27–29].

This study prevalence variation may reflect the non-homogeneity in SARS-CoV-2 risk for HCWs according to the considered country and its COVID-19 containment measures as well as the development of proper diagnostic algorithm, screening programmes at the workplace as well as effective contact tracing and management of index/suspected cases. At the same time, this heterogeneity might be, at least partially, attributable to the serological tests performance and to the kinetic of antibody production. There are intrinsic and extrinsic limitations in diagnostic tests that, if not fully considered, from an epidemiological and clinical viewpoint, might lead to potential biases on estimates and on medical decision-making.

The idea behind the use of three different case definitions for the study was based on the limitations reported in the literature concerning the current development of the SARS-CoV-2 testing technologies.

Therefore, assessing the impact of testing results, pathognomonic S&S and the kinetic of antibody production, when determining the SARS-CoV-2 prevalence, indicate that a test-only approach might reduce the validity of these studies. Using the data gathered in our multicentre serological study amongst HCWs, the aim was to highlight that SARS-CoV-2 serological point prevalence might result in an underestimation of the real percentage of HCWs infected by SARS-CoV-2.

In fact, when the prevalence of COVID-19 is based exclusively on the POCT results, the estimate was 6.7%, with only 59.5% of HCWs who reported a previous COVID-19 diagnosis were amongst those who received a positive POCT result. These findings are consistent with others recently reported in a large seroprevalence study carried out during COVID-19 first wave in Spain. In this study, the overall SARS-CoV-2 prevalence was found to be 11.8% (PCR and/or serological testing) and less than a third of those who resulted positive to the serological laboratory test reported a previous COVID-19 infection [16]. Whether in this study the unawareness could be related to the low proportion of workers tested with RT-PCR (COVID-19 symptoms or contact with index cases), in our study the discrepancy between those with a previous known infection and a POCT-positive result might suggest a rapid decay of antibody values refer to the comparison of diagnostic results between COVID-19/non-COVID-19 units. P*Statistically significant (P < 0.05).
Fig. 1. Probability in having an IgG (a) or IgM (b) positive result according to the time between SARS-CoV-2 infection diagnosis (RT-PCR on NPS) and the POCT execution.

Fig. 2. SARS-CoV2 infection frequency according to the diagnostic criteria considered.
tittres over a 4-month period. This is further corroborated by the fact that the SARS-CoV-2 infection prevalence found in our sample was lower, according to POCT result, than the one based on COVID-19 RT-PCR. In addition, considering that massive molecular screening test started in April 2020, SARS-CoV-2 infections occurred during the first 8 weeks of the pandemic might have been missed as resulted negative to both the first RT-PCR and the POCT, due to the delay in performing the test from the potential infection.

In order to further explore the potential SARS-CoV-2 prevalence in the context of this study, authors included an additional layer, that is the presence of self-reported COVID-19 pathognomonic S&S [22–25]. Although this case definition has probably low specificity, when compared to the one based on any diagnostic test, it must be considered that at the beginning of the epidemic the clinical features of SARS-CoV-2 infection were the only available criteria to be used for reaching a diagnosis. In addition, this latter clinical diagnostic approach is the only one extensively accessible in many remote areas of the world, even nowadays.

When including the HCWs who reported on the survey form COVID-19 pathognomonic S&S from February till April 2020, the prevalence was in line with the one obtained using diagnostics (9.6% and 10.0%, respectively) and higher than the one based on either POCT or RT-PCR (6.7% and 8.1%, respectively). As shown in Figure 2, the majority of positive HCWs would have been missed in the prevalence estimation if only diagnostic tests had been used.

The present study contributed to highlight at least two key issues when considering SARS-CoV-2 prevalence data among high-risk populations, such as HCWs, during the first wave of the pandemic.

First, diagnostic tests have relevant limitations [30] such as the fact that molecular tests might produce false-negative results when performed too early or too late during infection, that antigenic tests might have false-negative results in asymptomatic subjects [31] and that serological tests, mainly but not limited to POCT, have considerable risk of false-negative results both at the very beginning and months later the infection [13].

Second, COVID-19 prevalence could significantly change considering the diagnostic approach used. Indeed, serological tests are often considered as a whole, with no or minimal difference between point-of-care and laboratory tests, even if the analytical characteristics of the former are lower than those of their laboratory counterpart. As pointed out in a Cochrane systematic review, lateral flow assays have a sensitivity of at least 4% lower compared to laboratory tests, and this is not linked to the type of antibody (IgG 76%, IgM 51.4%, IgG and IgM 85.8%) [13]. Although a 4% decrease in sensitivity represents a small difference in a test, it could have a massive impact on positive predictive value (PPV) in setting with low prevalence and selected populations.

Based on the analytical characteristics of the POCT used in our study for the IgG component (sensitivity 97%, specificity 100%, as declared by the manufacturer [21]) and assuming the seroprevalence found in the Veneto Region serosurvey amongst HCWs (4.6%), the estimated predictive values were extremely high (PPV 100%, NPV 99.9%). However, based on the Cochrane systematic review previously mentioned, the analytical performance of this kind of tests should be carefully evaluated. In fact, the paper reports an average IgG/IgM sensitivity of 96% (95% CI 90.6–98.3) [13] which can have a relevant impact on the field use of these tests. Assuming that the estimated impact of the time elapsed on the antibodies detection ability is around 1% reduction, as found in our paper, reaching the above-mentioned 96% and applying the same infection prevalence, the PPV of the POCT resulted 82.2% (95% CI 39.7–97). This 18% reduction means that, amongst the HCWs who resulted positive at the POCT, only 82% (75/91 HCWs) were real positives.

A possible explanation for this performance may lay on the impact of SARS-CoV-2 antibody dynamics on serology. Antibodies are increasingly produced during the infection reaching the peak of detectability during the third week from symptoms onset [13]. Unfortunately, there are insufficient data to assess serological test sensitivity beyond the fifth week of infection [8, 13] and, therefore, as the median time from COVID-19 molecular diagnosis to POCT execution in our study was 125 days, we cannot be sure whether that 96% would remain stable or, more probably, decreases over time. In addition, our study provides a numerical estimation of the impact of time after COVID-19 diagnosis on the likelihood of having a serological positive result (at.1% every 10 days). Although further studies might be warranted to generalise our result to other POCT serological tests and to serology in itself, this estimate might be useful in understanding SARS-CoV-2 serological data and planning interventions for public health purposes.

Other studies are needed to really understand the meaning of our paper insights and if these findings could lead to the indication that prevalence studies already published should be at least interpreted in light of these tests’ limitations. For instance, the 8.7% (95% CI 6.7–10.9%) overall SARS-CoV-2 seroprevalence among HCWs, as reported by a recent meta-analysis [12], could probably represent an underestimation of the proportion of this target population who acquired COVID-19 over time.

Based on the current knowledge about the duration of SARS-CoV-2 antibodies in human blood, we can conclude that serological tests, certainly but presumably not limited to POCT, may not be the best predictors of real previous COVID-19 infections, unless carried out 3–5 weeks from the onset of infection. However, in case of seropositivity monitoring (i.e. public health case management purposes), the time interval between consecutive testing should be very limited, ideally 4 weeks, particularly when high-risk populations are considered.

Acknowledgments. Bellamoli Claudio, Bertaiola Vanda, Bongiovanni Giulio, Capra Claudio, Cassin Emanuela, Derboni Morena, Fadini Marco, Giarrdini Federico, Monaco Cinzia, Morandini Emanuela, Piva Enrico, Porcari Irene, Spallinger Thomas, Zanetti Giuliana.

Author contributions. MC, EC and ET participated in the design and implementation of the study. This analysis was conceived by MC and MM. Data were analysed by MC, SG and MM. The first draft was jointly written by MC, LG and MM. All authors revised the manuscript for content. All authors read and approved the final manuscript.

Financial support. This study was funded by Cariverona Foundation (ENACT Fund 2020), Italy. The sole responsibility lies with the authors of this manuscript and the Cariverona Foundation is not responsible for any use that may be made of the information contained therein.

Conflict of interest. None.

Data availability statement. The data that support the findings of this study are available from the corresponding author with the permission of the ENACT Working Group.

References

1. Guzzetta G et al. (2021) Impact of a nationwide lockdown on SARS-CoV-2 transmissibility, Italy. Emerging Infectious Diseases 27, 267–270.
2. World Health Organization (WHO) (2020) Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (Accessed 12 March 2021).

3. Task Force COVID-19 del Dipartimento Malattie Infettive e Servizio di Informatica. Epidemia COVID-19, Aggiornamento nazionale: 27 ottobre 2020. In: Istituto Superiore di Sanità (ISS). Available at https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_27-ottobre-2020.pdf (Accessed 30 October 2020).

4. Houlihan CF et al. (2020) Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers. The Lancet 396, e6–e7.

5. Karlsson U and Fraenkel CJ (2020) Covid-19: risks to healthcare workers and their families. British Medical Journal 371, m3944.

6. Mathur G and Mathur S (2020) Antibody testing for COVID-19. American Journal of Clinical Pathology 154, 1–3.

7. Zainol Rashid ZOS et al. (2020) Diagnostic performance of COVID-19 serology assays. The Malaysian Journal of Pathology 42, 13–21.

8. Lisboa Bastos M et al. (2020) Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. British Medical Journal 370, m2516.

9. Boger B et al. (2021) Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19. American Journal of Infection Control 49, 21–29.

10. Stekler JD et al. (2016) Performance of determine combo and other point-of-care HIV tests among Seattle MSM. Journal of Clinical Virology 76, 8–13.

11. Zorzi A et al. (2017) Field evaluation of two point-of-care tests for syphilis among men who have sex with men, Verona, Italy. Sexually Transmitted Infections 93, S51–S58.

12. Bouzid D et al. (2021) Rapid diagnostic tests for infectious diseases in the emergency department. Clinical Microbiology and Infection 27, 182–191.

13. Deeks JJ et al. (2020) Antibody tests for identification of current and past infection with SARS-CoV-2. The Cochrane Database of Systematic Reviews 6, CD013652.

14. Grenache DG et al. (2020) Antibody testing for COVID-19. American Journal of Clinical Pathology 154, 425–426.

15. Galanis P et al. (2021) Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. The Journal of Hospital Infection 108, 120–134.

16. Varona JF et al. (2021) Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain. International Journal of Epidemiology 50, 400–409.

17. Pallett SJC et al. (2020) Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study. The Lancet Respiratory Medicine 8, 885–894.

18. World Health Organization (WHO). Prevention, identification and management of health worker infection in the context of COVID-19: interim guidance, 30 October 2020. Available at https://apps.who.int/iris/handle/10665/336265 (Accessed 17 November 2020).

19. Sahu AK et al. (2020) COVID-19 in health care workers -- a systematic review and meta-analysis. The American Journal of Emergency Medicine 38, 1727–1731.

20. Plebani M et al. (2020) SARS-CoV-2 serosurvey in health care workers of the Veneto Region. Clinical Chemistry and Laboratory Medicine 58, 2107–2111.

21. Healgen Scientific LLC (2020) COVID-19 IgG/IgM rapid test cassette (whole blood/serum/plasma) – instruction for use. Available at chrome-extension://efaidnbmnnibcpacjgjejeiilmenafoe/viewer.html?pdfurl=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F138438%2Fdownload&clen=545412&chunk=true (Accessed 12 February 2021).

22. Li LQ et al. (2020) COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. Journal of Medical Virology 92, 577–583.

23. Fu L et al. (2020) Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. The Journal of Infection 80, 656–665.

24. Meng X, Deng Y, Dai Z and Meng Z (2020) COVID-19 and anosmia: a review based on up-to-date knowledge. American Journal of Otolaryngology 41, 102581.

25. Guo M et al. (2021) Potential intestinal infection and fecal-oral transmission of SARS-CoV-2. Nature Reviews Gastroenterology & Hepatology 18, 269–283.

26. Task Force COVID-19 del Dipartimento Malattie Infettive e Servizio di Informatica ISdS: Epidemia COVID-19, Aggiornamento nazionale: 22 gennaio 2021. In.: Istituto Superiore di Sanità (ISS). Available at https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_22-gennaio-2021.pdf (Accessed 12 February 2021).

27. Schwartz KL et al. (2020) Epidemiology, clinical characteristics, household transmission, and lethality of severe acute respiratory syndrome coronavirus-2 infection among healthcare workers in Ontario, Canada. PLoS ONE 15, e0244477.

28. Chou R et al. (2020) Epidemiology of and risk factors for coronavirus infection in health care workers: a living rapid review. Annals of Internal Medicine 173, 120–136.

29. Grant JJ et al. (2021) Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS Trust. Infection Control and Hospital Epidemiology 42, 212–214.

30. Mina MJ and Anderson K (2021) COVID-19 testing: one size does not fit all. Science 371, 126–127.

31. Dinnes J et al. (2020) Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. The Cochrane Database of Systematic Reviews 8, CD013705.